Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Urokinase Market is estimated to be USD 2.58 Bn in 2023 and is expected to reach USD 3.24 Bn by 2028, growing at a CAGR of 4.65%.

The global urokinase market is a growing segment of the pharmaceutical industry, driven by the rising prevalence of pulmonary embolism globally, the usage of urokinase in the treatment of cardiovascular disease, and growing instances of intracerebral hemorrhage.

The urokinase market is being driven by the increasing prevalence of pulmonary embolism (PE), a condition characterized by blood clots in the lungs. Urokinase, a thrombolytic agent, is used to dissolve these clots and is naturally produced by the human body. It plays a crucial role in breaking down blood clots in the blood vessels.

However, it's important to note that urokinase does come with certain side effects. Common side effects include bleeding, fever, headache, nausea, and vomiting. In rare cases, more severe side effects like allergic reactions can occur. Allergic reactions may manifest as hives, difficulty breathing, swelling of the face or throat, chest pain, or a rapid or irregular heartbeat, necessitating immediate medical attention. These potential side effects can limit the market's growth.

Despite these challenges, there are opportunities in the market. Ongoing research is exploring the use of urokinase in stroke patients. Urokinase, known for its ability to dissolve blood clots, has been successfully used in treating other clot-related conditions like pulmonary embolism and deep vein thrombosis.

The urokinase market is highly competitive, featuring numerous players involved in developing and marketing urokinase products. The report offers an in-depth analysis of market competitors, including a financial performance analysis of publicly listed companies. It also provides detailed information on recent developments and the competitive landscape.

Key players in the market include Abbott Laboratories, Merck KGaA, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and Zydus Cadila Healthcare Ltd.

Market Segmentations

• By Type, the market is classified into High Molecular Weight Urokinase and Low Molecular Weight Urokinase. High molecular weight urokinase has a larger molecular weight than low molecular weight urokinase and is typically used for the treatment of arterial thrombosis. Low molecular weight urokinase has a lower molecular weight and is used for the treatment of venous thrombosis.
• By Dose Strength, the market is classified into 250,000 IU, 500,000 IU, and 750,000 IU. The 500,000 IU hold the largest market share. It is because the 500,000 IU dose strength are more commonly used because it provides an effective balance between potency and safety.
• By Indication, the market is classified into Deep Vein Thrombosis, Pulmonary Embolism, and Myocardial Infarction. Deep Vein Thrombosis has the largest market share. This is due to the high prevalence of DVT and the effectiveness of urokinase in treating this condition.
• By Applications, the market is classified into Hospitals & Clinics, Ambulatory Surgical Centers, and Others. The Hospitals & Clinics has the largest market share. It is due to the high demand for urokinase in these facilities. Hospitals and clinics are the primary settings where urokinase is used, as these facilities have the resources and staff to treat patients with serious medical conditions such as deep vein thrombosis, pulmonary embolism, and myocardial infarction.
• By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific. The Americas region for the urokinase market is expected to be the largest due to the presence of well-established healthcare infrastructure and a high incidence of blood clotting disorders.

Company Profiles

• Abbott Laboratories
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Genentech, Inc.
• Hainan Poly Pharm Co., Ltd.
• Hualan Biological Engineering, Inc.
• JCR Pharmaceuticals Co., Ltd.
• Jiangsu Aidea Pharmaceutical Co., Ltd.
• Livzon Pharmaceutical Group, Inc.
• Merck KGaA
• Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
• Novartis International Ag
• Pfizer, Inc.
• Sanofi SA
• Shandong Qidu Pharmaceutical Co., Ltd.
• Shanghai RAAS Blood Products Co., Ltd.
• Sino Biological, Inc.
• Teva Pharmaceutical Industries Ltd.
• Wuhan Humanwell Healthcare Group Co., Ltd.
• Zydus Cadila Healthcare Ltd.

Key Attributes:

Key Topics Covered:

1 Report Description

1.1 Study Objectives

1.2 Market Definition

1.3 Currency

1.4 Years Considered

1.5 Language

1.6 Key Stakeholders

2 Research Methodology

2.1 Research Process

2.2 Data Collection and Validation

2.3 Market Size Estimation

2.4 Assumptions of the Study

2.5 Limitations of the Study

3 Executive Summary

3.1 Introduction

3.2 Market Size, Segmentations, and Outlook

4 Market Dynamics

4.1 Impact Analysis

4.2 Drivers

4.2.1 Rising Prevalence of Pulmonary Embolism Globally

4.2.2 Usage of Urokinase in the Treatment of Cardiovascular Disease

4.2.3 Growing Instances of Intracerebral Hemorrhage

4.3 Restraints

4.3.1 Urokinase is Contraindicated in Patients Suffering from Cancer and Brain Tumor

4.4 Opportunities

4.4.1 Ongoing Research Activities for Using Urokinase in Stroke Patients

4.4.2 Economic Development and Substantial Infrastructure Development

4.5 Challenges

4.5.1 Side Effects Such as Urticaria, Difficulty in Breathing, and Swelling of the Face

5 Market Analysis

5.1 Regulatory Scenario

5.2 Porter's Five Forces Analysis

5.3 PESTLE Analysis

5.4 SWOT Analysis

5.5 Impact of COVID-19

5.6 Ansoff Matrix Analysis

6 Global Urokinase Market, By Type

6.1 Introduction

6.2 High Molecular Weight

6.3 Low Molecular Weight

7 Global Urokinase Market, By Dose Strength

7.1 Introduction

7.2 250,000 IU

7.3 500,000 IU

7.4 750,000 IU

8 Global Urokinase Market, By Indication

8.1 Introduction

8.2 Deep Vein Thrombosis

8.3 Pulmonary Embolism

8.4 Myocardial Infarction

9 Global Urokinase Market, By Applications

9.1 Introduction

9.2 Hospitals & Clinics

9.3 Ambulatory Surgical Centers

9.4 Others (Research Institutions, Pharmaceutical Companies, & CRO)

For more information about this report visit https://www.researchandmarkets.com/r/upm2bn

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900